ID   CP21A_HUMAN             Reviewed;         494 AA.
AC   P08686; A2BHY6; P04033; Q01204; Q08AG8; Q16749; Q16806; Q5ST44;
AC   Q96NU8;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   10-MAY-2017, entry version 201.
DE   RecName: Full=Steroid 21-hydroxylase;
DE            EC=1.14.14.16 {ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825};
DE   AltName: Full=21-OHase;
DE   AltName: Full=Cytochrome P-450c21;
DE   AltName: Full=Cytochrome P450 21;
DE   AltName: Full=Cytochrome P450 XXI;
DE   AltName: Full=Cytochrome P450-C21;
DE   AltName: Full=Cytochrome P450-C21B;
GN   Name=CYP21A2; Synonyms=CYP21, CYP21B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE CYP21A2*1A).
RX   PubMed=3486422; DOI=10.1073/pnas.83.9.2841;
RA   Higashi Y., Yoshioka H., Yamane M., Gotoh O., Fujii-Kuriyama Y.;
RT   "Complete nucleotide sequence of two steroid 21-hydroxylase genes
RT   tandemly arranged in human chromosome: a pseudogene and a genuine
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:2841-2845(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ALLELE CYP21A2*1B) (ISOFORM
RP   1).
RX   PubMed=3487786; DOI=10.1073/pnas.83.14.5111;
RA   White P.C., New M.I., Dupont B.;
RT   "Structure of human steroid 21-hydroxylase genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5111-5115(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT AH3 THR-268, VARIANTS LEU-9
RP   INS; ARG-102 AND SER-493, AND INVOLVEMENT IN AH3.
RX   PubMed=3038528;
RA   Rodrigues N.R., Dunham I., Yu C.Y., Carroll M.C., Porter R.R.,
RA   Campbell R.D.;
RT   "Molecular characterization of the HLA-linked steroid 21-hydroxylase B
RT   gene from an individual with congenital adrenal hyperplasia.";
RL   EMBO J. 6:1653-1661(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT AH3 LEU-281, AND VARIANT
RP   LEU-9 INS.
RX   PubMed=3267225; DOI=10.1172/JCI113562;
RA   Globerman H., Amor M., Parker K.L., New M.I., White P.C.;
RT   "Nonsense mutation causing steroid 21-hydroxylase deficiency.";
RL   J. Clin. Invest. 82:139-144(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS LEU-9 INS; ARG-102 AND
RP   SER-493, AND VARIANTS AH3 HIS-339 AND SER-453.
RC   TISSUE=Peripheral blood;
RX   PubMed=1406709; DOI=10.1210/mend.6.8.1406709;
RA   Helmberg A., Tusie-Luna M.-T., Tabarelli M., Kofler R., White P.C.;
RT   "R339H and P453S: CYP21 mutations associated with nonclassic steroid
RT   21-hydroxylase deficiency that are not apparent gene conversions.";
RL   Mol. Endocrinol. 6:1318-1322(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=19505723; DOI=10.1016/j.molimm.2009.04.033;
RA   Blasko B., Banlaki Z., Gyapay G., Pozsonyi E., Sasvari-Szekely M.,
RA   Rajczy K., Fust G., Szilagyi A.;
RT   "Linkage analysis of the C4A/C4B copy number variation and
RT   polymorphisms of the adjacent steroid 21-hydroxylase gene in a healthy
RT   population.";
RL   Mol. Immunol. 46:2623-2629(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE CYP21A2*6) (ISOFORM 2).
RC   TISSUE=Adrenal gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   SER-493.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 109-185, AND VARIANT AH3 ASN-172.
RX   PubMed=8485582; DOI=10.1038/ng0393-260;
RA   Collier S., Tassabehji M., Sinnott P., Strachan T.;
RT   "A de novo pathological point mutation at the 21-hydroxylase locus:
RT   implications for gene conversion in the human genome.";
RL   Nat. Genet. 3:260-265(1993).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 149-182, AND VARIANT AH3 ASN-172.
RX   PubMed=3871526; DOI=10.1073/pnas.82.2.521;
RA   Carroll M.C., Campbell R.D., Porter R.R.;
RT   "Mapping of steroid 21-hydroxylase genes adjacent to complement
RT   component C4 genes in HLA, the major histocompatibility complex in
RT   man.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:521-525(1985).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 149-182, AND VARIANT AH3 ASN-172.
RX   PubMed=3257825; DOI=10.1073/pnas.85.5.1600;
RA   Amor M., Parker K.L., Globerman H., New M.I., White P.C.;
RT   "Mutation in the CYP21B gene (Ile-172-->Asn) causes steroid 21-
RT   hydroxylase deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1600-1604(1988).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 265-494 (ISOFORM 1), AND VARIANT AH3
RP   LEU-281.
RX   PubMed=3497399; DOI=10.1073/pnas.84.16.5858;
RA   Matteson K.J., Phillips J.A. III, Miller W.L., Chung B.C.,
RA   Orlando P.J., Frisch H., Ferrandez A., Burr I.M.;
RT   "P450XXI (steroid 21-hydroxylase) gene deletions are not found in
RT   family studies of congenital adrenal hyperplasia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:5858-5862(1987).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 29-494 IN COMPLEX WITH HEME
RP   AND PROGESTERONE, FUNCTION, COFACTOR, AND CATALYTIC ACTIVITY.
RX   PubMed=25855791; DOI=10.1074/jbc.M115.646307;
RA   Pallan P.S., Wang C., Lei L., Yoshimoto F.K., Auchus R.J.,
RA   Waterman M.R., Guengerich F.P., Egli M.;
RT   "Human Cytochrome P450 21A2, the major steroid 21-hydroxylase:
RT   structure of the enzyme-progesterone substrate complex and rate-
RT   limiting c-h bond cleavage.";
RL   J. Biol. Chem. 290:13128-13143(2015).
RN   [16]
RP   CHARACTERIZATION OF VARIANT AH3 LEU-281, AND MUTAGENESIS OF SER-268
RP   AND CYS-428.
RX   PubMed=1864962; DOI=10.1172/JCI115334;
RA   Wu D.-A., Chung B.-C.;
RT   "Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281, and
RT   Ser268 result in complete, partial, or no loss of enzymatic activity,
RT   respectively.";
RL   J. Clin. Invest. 88:519-523(1991).
RN   [17]
RP   REVIEW ON AH3 VARIANTS.
RA   Gunn S.K., Sherman L.D., Therrell B.L., Owerbach D.I.;
RT   "Molecular genetics of 21-hydroxylase deficient late-onset adrenal
RT   hyperplasia.";
RL   Semin. Reprod. Endocrinol. 11:347-352(1993).
RN   [18]
RP   REVIEW ON AH3 VARIANTS, AND GENE CONVERSION.
RX   PubMed=8081391; DOI=10.1002/humu.1380030408;
RA   White P.C., Tusie-Luna M.-T., New M.I., Speiser P.W.;
RT   "Mutations in steroid 21-hydroxylase (CYP21).";
RL   Hum. Mutat. 3:373-378(1994).
RN   [19]
RP   VARIANTS AH3 LEU-211 AND LEU-281.
RX   PubMed=3260007; DOI=10.1056/NEJM198807073190104;
RA   Speiser P.W., New M.I., White P.C.;
RT   "Molecular genetic analysis of nonclassic steroid 21-hydroxylase
RT   deficiency associated with HLA-B14,DR1.";
RL   N. Engl. J. Med. 319:19-23(1988).
RN   [20]
RP   VARIANTS AH3 ASN-172 AND TRP-356, AND VARIANT LEU-9 INS.
RX   PubMed=2303461;
RA   Chiou S.-H., Hu M.-C., Chung B.-C.;
RT   "A missense mutation at Ile172-->Asn or Arg356-->Trp causes steroid
RT   21-hydroxylase deficiency.";
RL   J. Biol. Chem. 265:3549-3552(1990).
RN   [21]
RP   VARIANT AH3 ASN-172.
RX   PubMed=1937474; DOI=10.1007/BF00201731;
RA   Partanen J., Campbell R.D.;
RT   "Substitution of Ile-172 to Asn in the steroid 21-hydroxylase B
RT   (P450c21B) gene in a Finnish patient with the simple virilizing form
RT   of congenital adrenal hyperplasia.";
RL   Hum. Genet. 87:716-720(1991).
RN   [22]
RP   VARIANT AH3 LEU-30, AND VARIANT THR-268.
RX   PubMed=2072928; DOI=10.1210/mend-5-5-685;
RA   Tusie-Luna M.T., Speiser P.W., Dumic M., New M.I., White P.C.;
RT   "A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic
RT   steroid 21-hydroxylase deficiency allele.";
RL   Mol. Endocrinol. 5:685-692(1991).
RN   [23]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281 AND
RP   TRP-356.
RX   PubMed=1644925; DOI=10.1172/JCI115897;
RA   Speiser P.W., Dupont J., Zhu D., Serrat J., Buegeleisen M.,
RA   Tusie-Luna M.-T., Lesser M., New M.I., White P.C.;
RT   "Disease expression and molecular genotype in congenital adrenal
RT   hyperplasia due to 21-hydroxylase deficiency.";
RL   J. Clin. Invest. 90:584-595(1992).
RN   [24]
RP   VARIANT AH3 SER-453.
RX   PubMed=1406699; DOI=10.1210/mend.6.8.1406699;
RA   Owerbach D., Sherman L., Ballard A.L., Azziz R.;
RT   "Pro-453 to Ser mutation in CYP21 is associated with nonclassic
RT   steroid 21-hydroxylase deficiency.";
RL   Mol. Endocrinol. 6:1211-1215(1992).
RN   [25]
RP   VARIANTS AH3 LEU-105; SER-291 AND SER-453.
RX   PubMed=1496017; DOI=10.1073/pnas.89.15.7232;
RA   Wedell A., Ritzen E.M., Haglund-Stengler B., Luthman H.;
RT   "Steroid 21-hydroxylase deficiency: three additional mutated alleles
RT   and establishment of phenotype-genotype relationships of common
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7232-7236(1992).
RN   [26]
RP   VARIANT AH3 PRO-483.
RX   PubMed=8478006; DOI=10.1007/BF00218263;
RA   Wedell A., Luthman H.;
RT   "Steroid 21-hydroxylase (P450c21): a new allele and spread of
RT   mutations through the pseudogene.";
RL   Hum. Genet. 91:236-240(1993).
RN   [27]
RP   VARIANTS AH3 ASN-172; ASN-236; LEU-281 AND PRO-483, AND VARIANT
RP   SER-493.
RX   PubMed=7749410; DOI=10.1002/humu.1380050205;
RA   Barbat B., Bogyo A., Raux-Demay M.-C., Kuttenn F., Boue J.,
RA   Simon-Bouy B., Serre J.-L., Boue A., Mornet E.;
RT   "Screening of CYP21 gene mutations in 129 French patients affected by
RT   steroid 21-hydroxylase deficiency.";
RL   Hum. Mutat. 5:126-130(1995).
RN   [28]
RP   VARIANT AH3 ASP-380.
RX   PubMed=9067760;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:2<181::AID-HUMU12>3.0.CO;2-Z;
RA   Kirby-Keyser L., Porter C.C., Donohoue P.A.;
RT   "E380D: a novel point mutation of CYP21 in an HLA-homozygous patient
RT   with salt-losing congenital adrenal hyperplasia due to 21-hydroxylase
RT   deficiency.";
RL   Hum. Mutat. 9:181-182(1997).
RN   [29]
RP   VARIANTS AH3 PRO-356 AND GLN-356.
RX   PubMed=9187661; DOI=10.1007/s004390050436;
RA   Lajic S., Levo A., Nikoshkov A., Lundberg Y., Partanen J., Wedell A.;
RT   "A cluster of missense mutations at Arg356 of human steroid 21-
RT   hydroxylase may impair redox partner interaction.";
RL   Hum. Genet. 99:704-709(1997).
RN   [30]
RP   VARIANTS AH3 LEU-105 AND SER-453.
RX   PubMed=8989258; DOI=10.1210/jcem.82.1.3678;
RA   Nikoshkov A., Lajic S., Holst M., Wedell A., Luthman H.;
RT   "Synergistic effect of partially inactivating mutations in steroid 21-
RT   hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 82:194-199(1997).
RN   [31]
RP   VARIANTS AH3, AND VARIANTS.
RX   PubMed=9580109; DOI=10.1007/s004390050672;
RA   Ordonez-Sanchez M.L., Ramirez-Jimenez S., Lopez-Gutierrez A.U.,
RA   Riba L., Gamboa-Cardiel S., Cerrillo-Hinojosa M.,
RA   Altamirano-Bustamante N., Calzada-Leon R., Robles-Valdes C.,
RA   Mendoza-Morfin F., Tusie-Luna M.T.;
RT   "Molecular genetic analysis of patients carrying steroid 21-
RT   hydroxylase deficiency in the Mexican population: identification of
RT   possible new mutations and high prevalence of apparent germ-line
RT   mutations.";
RL   Hum. Genet. 102:170-177(1998).
RN   [32]
RP   VARIANTS AH3 GLU-196 DEL; SER-291 AND PRO-483.
RX   PubMed=9497336; DOI=10.1074/jbc.273.11.6163;
RA   Nikoshkov A., Lajic S., Vlamis-Gardikas A., Tranebjaerg L., Holst M.,
RA   Wedell A., Luthman H.;
RT   "Naturally occurring mutants of human steroid 21-hydroxylase (P450c21)
RT   pinpoint residues important for enzyme activity and stability.";
RL   J. Biol. Chem. 273:6163-6165(1998).
RN   [33]
RP   VARIANT AH3 GLN-30, CHARACTERIZATION OF VARIANT AH3 GLN-30,
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND DOMAIN.
RX   PubMed=10198222; DOI=10.1006/bbrc.1999.0482;
RA   Lajic S., Nikoshkov A., Holst M., Wedell A.;
RT   "Effects of missense mutations and deletions on membrane anchoring and
RT   enzyme function of human steroid 21-hydroxylase (P450c21).";
RL   Biochem. Biophys. Res. Commun. 257:384-390(1999).
RN   [34]
RP   VARIANTS AH3 LEU-30; VAL-90; ASN-172; ALA-178; LEU-281; CYS-291;
RP   HIS-354; TRP-356 AND SER-453.
RX   PubMed=10364682; DOI=10.1159/000022866;
RA   Lobato M.N., Ordonez-Sanchez M.L., Tusie-Luna M.T., Meseguer A.;
RT   "Mutation analysis in patients with congenital adrenal hyperplasia in
RT   the Spanish population: identification of putative novel steroid 21-
RT   hydroxylase deficiency alleles associated with the classic form of the
RT   disease.";
RL   Hum. Hered. 49:169-175(1999).
RN   [35]
RP   VARIANTS AH3 TYR-169; LEU-281 AND GLN-356.
RX   PubMed=10094562;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:2<172::AID-HUMU17>3.3.CO;2-E;
RA   Witchel S.F., Smith R., Suda-Hartman M.;
RT   "Identification of CYP21 mutations, one novel, by single strand
RT   conformational polymorphism (SSCP) analysis.";
RL   Hum. Mutat. 13:172-172(1999).
RN   [36]
RP   VARIANTS AH3 LEU-30; GLU-64; ASN-172; ASN-236; LEU-281; SER-291;
RP   TRP-356 AND VAL-362.
RX   PubMed=10408778;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<482::AID-HUMU8>3.0.CO;2-0;
RA   Ohlsson G., Mueller J., Skakkebaek N.E., Schwartz M.;
RT   "Steroid 21-hydroxylase deficiency: mutational spectrum in Denmark,
RT   three novel mutations, and in vitro expression analysis.";
RL   Hum. Mutat. 13:482-486(1999).
RN   [37]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281 AND
RP   TRP-356.
RX   PubMed=10408786;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<505::AID-HUMU16>3.0.CO;2-0;
RA   Kapelari K., Ghanaati Z., Wollmann H., Ventz M., Ranke M.B.,
RA   Kofler R., Peters H.;
RT   "A rapid screening for steroid 21-hydroxylase mutations in patients
RT   with congenital adrenal hyperplasia.";
RL   Hum. Mutat. 13:505-505(1999).
RN   [38]
RP   VARIANTS AH3 LEU-281; TRP-356 AND SER-424.
RX   PubMed=10443693; DOI=10.1210/jcem.84.8.5937;
RA   Billerbeck A.E.C., Bachega T.A.S.S., Frazatto E.T., Nishi M.Y.,
RA   Goldberg A.C., Marin M.L.C., Madureira G., Monte O., Arnhold I.J.P.,
RA   Mendonca B.B.;
RT   "A novel missense mutation, GLY424SER, in Brazilian patients with 21-
RT   hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 84:2870-2872(1999).
RN   [39]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; TRP-356 AND SER-493, AND
RP   VARIANT THR-268.
RX   PubMed=10496074; DOI=10.1007/s100380050167;
RA   Asanuma A., Ohura T., Ogawa E., Sato S., Igarashi Y., Matsubara Y.,
RA   Iinuma K.;
RT   "Molecular analysis of Japanese patients with steroid 21-hydroxylase
RT   deficiency.";
RL   J. Hum. Genet. 44:312-317(1999).
RN   [40]
RP   VARIANTS AH3 ASN-172 AND TRP-356.
RX   PubMed=10051010;
RA   Lako M., Ramsden S., Campbell R.D., Strachan T.;
RT   "Mutation screening in British 21-hydroxylase deficiency families and
RT   development of novel microsatellite based approaches to prenatal
RT   diagnosis.";
RL   J. Med. Genet. 36:119-124(1999).
RN   [41]
RP   VARIANTS AH3 LEU-281 AND SER-453, AND VARIANTS THR-268 AND SER-493.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [42]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [43]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; GLY-281; PHE-300; CYS-354;
RP   TRP-356 AND SER-453.
RX   PubMed=10720040; DOI=10.1210/jcem.85.3.6441;
RA   Krone N., Braun A., Roscher A.A., Knorr D., Schwarz H.P.;
RT   "Predicting phenotype in steroid 21-hydroxylase deficiency?
RT   Comprehensive genotyping in 155 unrelated, well defined patients from
RT   southern Germany.";
RL   J. Clin. Endocrinol. Metab. 85:1059-1065(2000).
RN   [44]
RP   VARIANTS AH3 LEU-30; ASN-172; PRO-261; TRP-356 AND PRO-483.
RX   PubMed=11598371; DOI=10.1159/000049992;
RA   Loke K.Y., Lee Y.S., Lee W.W.R., Poh L.K.S.;
RT   "Molecular analysis of CYP-21 mutations for congenital adrenal
RT   hyperplasia in Singapore.";
RL   Horm. Res. 55:179-184(2001).
RN   [45]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; MET-317; TRP-356; CYS-435 AND
RP   SER-453.
RX   PubMed=11232002; DOI=10.1210/jcem.86.1.7131;
RA   Deneux C., Tardy V., Dib A., Mornet E., Billaud L., Charron D.,
RA   Morel Y., Kuttenn F.;
RT   "Phenotype-genotype correlation in 56 women with nonclassical
RT   congenital adrenal hyperplasia due to 21-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 86:207-213(2001).
RN   [46]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; SER-291; TRP-356; SER-424;
RP   HIS-426; SER-453 AND PRO-483, AND CHARACTERIZATION OF VARIANT AH3
RP   HIS-426.
RX   PubMed=11600539; DOI=10.1210/jcem.86.10.7898;
RA   Baumgartner-Parzer S.M., Schulze E., Waldhaeusl W., Pauschenwein S.,
RA   Rondot S., Nowotny P., Meyer K., Frisch H., Waldhauser F.,
RA   Vierhapper H.;
RT   "Mutational spectrum of the steroid 21-hydroxylase gene in Austria:
RT   identification of a novel missense mutation.";
RL   J. Clin. Endocrinol. Metab. 86:4771-4775(2001).
RN   [47]
RP   VARIANT AH3 TRP-363.
RX   PubMed=11746135; DOI=10.1002/pd.167;
RA   Levo A., Partanen J.;
RT   "Novel mutations in the human CYP21 gene.";
RL   Prenat. Diagn. 21:885-889(2001).
RN   [48]
RP   VARIANTS AH3 LEU-30; ASN-172; LEU-281; LEU-283; TRP-356 AND SER-453.
RX   PubMed=12222711; DOI=10.1080/080352502760148595;
RA   Ezquieta B., Cueva E., Varela J., Oliver A., Fernandez J., Jariego C.;
RT   "Non-classical 21-hydroxylase deficiency in children: association of
RT   adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the
RT   risk of compound heterozygosity with severe mutations.";
RL   Acta Paediatr. 91:892-898(2002).
RN   [49]
RP   VARIANTS HYPERANDROGENISM MET-304; SER-375 AND SER-453, AND
RP   CHARACTERIZATION OF VARIANTS HYPERANDROGENISM MET-304; SER-375 AND
RP   SER-453.
RX   PubMed=12050257; DOI=10.1210/jcem.87.6.8525;
RA   Lajic S., Clauin S., Robins T., Vexiau P., Blanche H.,
RA   Bellanne-Chantelot C., Wedell A.;
RT   "Novel mutations in CYP21 detected in individuals with
RT   hyperandrogenism.";
RL   J. Clin. Endocrinol. Metab. 87:2824-2829(2002).
RN   [50]
RP   VARIANTS AH3 CYS-408 AND SER-424.
RX   PubMed=12213891; DOI=10.1210/jc.2001-011939;
RA   Billerbeck A.E.C., Mendonca B.B., Pinto E.M., Madureira G.,
RA   Arnhold I.J.P., Bachega T.A.S.S.;
RT   "Three novel mutations in CYP21 gene in Brazilian patients with the
RT   classical form of 21-hydroxylase deficiency due to a founder effect.";
RL   J. Clin. Endocrinol. Metab. 87:4314-4317(2002).
RN   [51]
RP   VARIANTS AH3 THR-15; LEU-30; ASN-172; LEU-281 AND SER-453.
RX   PubMed=12887291; DOI=10.1530/eje.0.1490137;
RA   Dolzan V., Stopar-Obreza M., Zerjav-Tansek M., Breskvar K.,
RA   Krzisnik C., Battelino T.;
RT   "Mutational spectrum of congenital adrenal hyperplasia in Slovenian
RT   patients: a novel Ala15Thr mutation and Pro30Leu within a larger gene
RT   conversion associated with a severe form of the disease.";
RL   Eur. J. Endocrinol. 149:137-144(2003).
RN   [52]
RP   VARIANTS AH3 LEU-30; LEU-62; ASN-172; LEU-281; PRO-341; TRP-356;
RP   SER-453 AND PRO-483.
RX   PubMed=12788866; DOI=10.1210/jc.2002-021433;
RA   Pinto G., Tardy V., Trivin C., Thalassinos C., Lortat-Jacob S.,
RA   Nihoul-Fekete C., Morel Y., Brauner R.;
RT   "Follow-up of 68 children with congenital adrenal hyperplasia due to
RT   21-hydroxylase deficiency: relevance of genotype for management.";
RL   J. Clin. Endocrinol. Metab. 88:2624-2633(2003).
RN   [53]
RP   VARIANTS AH3 ASN-172; LEU-281; ARG-291; TYR-301; PRO-341; TRP-356 AND
RP   GLN-483.
RX   PubMed=12915679; DOI=10.1210/jc.2002-021681;
RA   Stikkelbroeck N.M., Hoefsloot L.H., de Wijs I.J., Otten B.J.,
RA   Hermus A.R., Sistermans E.A.;
RT   "CYP21 gene mutation analysis in 198 patients with 21-hydroxylase
RT   deficiency in The Netherlands: six novel mutations and a specific
RT   cluster of four mutations.";
RL   J. Clin. Endocrinol. Metab. 88:3852-3859(2003).
RN   [54]
RP   VARIANTS AH3 ASN-172; TRP-356 AND TRP-483.
RX   PubMed=14715874; DOI=10.1210/jc.2003-031056;
RA   Kharrat M., Tardy V., M'Rad R., Maazoul F., Jemaa L.B., Refai M.,
RA   Morel Y., Chaabouni H.;
RT   "Molecular genetic analysis of Tunisian patients with a classic form
RT   of 21-hydroxylase deficiency: identification of four novel mutations
RT   and high prevalence of Q318X mutation.";
RL   J. Clin. Endocrinol. Metab. 89:368-374(2004).
RN   [55]
RP   VARIANT AH3 HIS-124.
RX   PubMed=14676460; DOI=10.1159/000075587;
RA   Usui T., Nishisho K., Kaji M., Ikuno N., Yorifuji T., Yasuda T.,
RA   Kuzuya H., Shimatsu A.;
RT   "Three novel mutations in Japanese patients with 21-hydroxylase
RT   deficiency.";
RL   Horm. Res. 61:126-132(2004).
RN   [56]
RP   VARIANTS AH3 THR-15; LEU-30; LEU-281 AND SER-482, AND CHARACTERIZATION
RP   OF VARIANTS AH3 THR-15 AND SER-482.
RX   PubMed=15126570; DOI=10.1210/jc.2003-031630;
RA   Barbaro M., Lajic S., Baldazzi L., Balsamo A., Pirazzoli P.,
RA   Cicognani A., Wedell A., Cacciari E.;
RT   "Functional analysis of two recurrent amino acid substitutions in the
RT   CYP21 gene from Italian patients with congenital adrenal
RT   hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 89:2402-2407(2004).
RN   [57]
RP   VARIANTS AH3 LEU-30; ASN-172; ASN-236; GLU-237; LYS-239; LEU-281;
RP   SER-291; GLN-356; TRP-356; TYR-365; SER-453; LEU-479 AND PRO-483, AND
RP   VARIANT ARG-102.
RX   PubMed=15110320; DOI=10.1016/j.ymgme.2004.02.006;
RA   Zeng X., Witchel S.F., Dobrowolski S.F., Moulder P.V., Jarvik J.W.,
RA   Telmer C.A.;
RT   "Detection and assignment of CYP21 mutations using peptide mass
RT   signature genotyping.";
RL   Mol. Genet. Metab. 82:38-47(2004).
RN   [58]
RP   VARIANTS AH3 LEU-30; ASN-172 AND TRP-356.
RX   PubMed=16046588; DOI=10.1210/jc.2005-0379;
RA   Grigorescu Sido A., Weber M.M., Grigorescu Sido P., Clausmeyer S.,
RA   Heinrich U., Schulze E.;
RT   "21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients
RT   with classic congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 90:5769-5773(2005).
RN   [59]
RP   VARIANTS AH3 ARG-169; ARG-178; ARG-302 AND CYS-426, CHARACTERIZATION
RP   OF VARIANTS AH3 ARG-169; ARG-178; ARG-302 AND CYS-426, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=16984992; DOI=10.1210/jc.2006-0777;
RA   Grischuk Y., Rubtsov P., Riepe F.G., Groetzinger J., Beljelarskaia S.,
RA   Prassolov V., Kalintchenko N., Semitcheva T., Peterkova V.,
RA   Tiulpakov A., Sippell W.G., Krone N.;
RT   "Four novel missense mutations in the CYP21A2 gene detected in Russian
RT   patients suffering from the classical form of congenital adrenal
RT   hyperplasia: identification, functional characterization, and
RT   structural analysis.";
RL   J. Clin. Endocrinol. Metab. 91:4976-4980(2006).
RN   [60]
RP   VARIANTS AH3 LEU-30; LEU-62; ASN-172; TRP-356 AND SER-453, AND
RP   CHARACTERIZATION OF VARIANTS AH3 LEU-62 AND SER-453.
RX   PubMed=18319307; DOI=10.1210/jc.2007-2701;
RA   Menassa R., Tardy V., Despert F., Bouvattier-Morel C., Brossier J.P.,
RA   Cartigny M., Morel Y.;
RT   "p.H62L, a rare mutation of the CYP21 gene identified in two forms of
RT   21-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 93:1901-1908(2008).
RN   [61]
RP   VARIANTS AH3 ARG-56; LEU-62; ARG-107; PRO-142; ASN-172; TRP-356;
RP   CYS-408 AND SER-453, AND CHARACTERIZATION OF VARIANTS AH3 ARG-56;
RP   LEU-62; ARG-107; PRO-142; CYS-408 AND SER-453.
RX   PubMed=18381579; DOI=10.1210/jc.2007-2594;
RA   Soardi F.C., Barbaro M., Lau I.F., Lemos-Marini S.H., Baptista M.T.,
RA   Guerra-Junior G., Wedell A., Lajic S., de Mello M.P.;
RT   "Inhibition of CYP21A2 enzyme activity caused by novel missense
RT   mutations identified in Brazilian and Scandinavian patients.";
RL   J. Clin. Endocrinol. Metab. 93:2416-2420(2008).
RN   [62]
RP   VARIANTS AH3 GLN-121 AND SER-453, AND CHARACTERIZATION OF VARIANT AH3
RP   GLN-121.
RX   PubMed=18445671; DOI=10.1210/jc.2007-2646;
RA   Riepe F.G., Hiort O., Grotzinger J., Sippell W.G., Krone N.,
RA   Holterhus P.M.;
RT   "Functional and structural consequences of a novel point mutation in
RT   the CYP21A2 gene causing congenital adrenal hyperplasia: potential
RT   relevance of helix C for P450 oxidoreductase-21-hydroxylase
RT   interaction.";
RL   J. Clin. Endocrinol. Metab. 93:2891-2895(2008).
RN   [63]
RP   VARIANTS AH3 THR-77; PRO-167; ASN-172; THR-230; LYS-233; LEU-281;
RP   SER-291; ASP-292; LYS-320; PRO-341; HIS-354; TRP-356; TRP-369;
RP   CYS-408; SER-424; HIS-426 AND SER-453, AND CHARACTERIZATION OF
RP   VARIANTS AH3 PRO-167; ASN-172; LEU-281; ASP-292; LYS-320; TRP-369 AND
RP   SER-424.
RX   PubMed=20080860; DOI=10.1210/jc.2009-1202;
RA   Tardy V., Menassa R., Sulmont V., Lienhardt-Roussie A., Lecointre C.,
RA   Brauner R., David M., Morel Y.;
RT   "Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected
RT   in 46 patients affected with 21-hydroxylase deficiency and in one
RT   carrier.";
RL   J. Clin. Endocrinol. Metab. 95:1288-1300(2010).
RN   [64]
RP   VARIANT AH3 PHE-198.
RX   PubMed=21169732; DOI=10.3275/7417;
RA   Niceta M., Bono M., Fabiano C., Pojero F., Niceta F., Sammarco P.,
RA   Corsello G., Garofalo P.;
RT   "A large view of CYP21 locus among Sicilians and other populations:
RT   identification of a novel CYP21A2 variant in Sicily.";
RL   J. Endocrinol. Invest. 34:847-854(2011).
RN   [65]
RP   VARIANTS AH3 HIS-191 AND ASN-282, CHARACTERIZATION OF VARIANTS AH3
RP   HIS-191 AND ASN-282, FUNCTION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22014889; DOI=10.1016/j.metabol.2011.08.008;
RA   Concolino P., Mello E., Patrosso M.C., Penco S., Zuppi C.,
RA   Capoluongo E.;
RT   "p.H282N and p.Y191H: 2 novel CYP21A2 mutations in Italian congenital
RT   adrenal hyperplasia patients.";
RL   Metabolism 61:519-524(2012).
RN   [66]
RP   VARIANTS AH3 MET-12; PHE-113; 389-GLN--ALA-391 DEL AND PRO-450,
RP   VARIANTS CYS-16; GLY-202; LEU-267 AND MET-450, CHARACTERIZATION OF
RP   VARIANTS AH3 MET-12; PHE-113; 389-GLN--ALA-391 DEL; PRO-450 AND
RP   SER-482, CHARACTERIZATION OF VARIANTS CYS-16; GLY-202; LEU-267 AND
RP   MET-450, FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=27721825; DOI=10.1155/2016/4209670;
RA   de Paula Michelatto D., Karlsson L., Lusa A.L., Silva C.D.,
RA   Oestberg L.J., Persson B., Guerra-Junior G., de Lemos-Marini S.H.,
RA   Barbaro M., de Mello M.P., Lajic S.;
RT   "Functional and structural consequences of nine CYP21A2 mutations
RT   ranging from very mild to severe effects.";
RL   Int. J. Endocrinol. 2016:4209670-4209670(2016).
CC   -!- FUNCTION: Specifically catalyzes the 21-hydroxylation of steroids.
CC       Required for the adrenal synthesis of mineralocorticoids and
CC       glucocorticoids (PubMed:22014889). {ECO:0000269|PubMed:22014889,
CC       ECO:0000269|PubMed:25855791, ECO:0000269|PubMed:27721825}.
CC   -!- CATALYTIC ACTIVITY: A C(21) steroid + [reduced NADPH--hemoprotein
CC       reductase] + O(2) = a 21-hydroxy-C(21)-steroid + [oxidized NADPH--
CC       hemoprotein reductase] + H(2)O. {ECO:0000269|PubMed:16984992,
CC       ECO:0000269|PubMed:22014889, ECO:0000269|PubMed:25855791,
CC       ECO:0000269|PubMed:27721825}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:25855791};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.59 uM for 17-hydroxyprogesterone
CC         {ECO:0000269|PubMed:22014889};
CC         KM=12.5 uM for for 17-hydroxyprogesterone (at 37 degrees
CC         Celsius) {ECO:0000269|PubMed:27721825};
CC         KM=1.05 uM for progesterone {ECO:0000269|PubMed:22014889};
CC         Vmax=5.8 nmol/min/mg enzyme {ECO:0000269|PubMed:22014889};
CC         Vmax=0.5 nmol/min/mg enzyme (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:27721825};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein {ECO:0000269|PubMed:10198222}. Microsome membrane
CC       {ECO:0000269|PubMed:10198222}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10198222}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P08686-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08686-2; Sequence=VSP_046264, VSP_046265;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The leucine-rich hydrophobic amino acid N-terminal region
CC       probably helps to anchor the protein to the microsomal membrane.
CC       {ECO:0000269|PubMed:10198222}.
CC   -!- POLYMORPHISM: Seven non deleterious alleles are known: CYP21A2*1A,
CC       CYP21A2*1B, CYP21A2*2, CYP21A2*3, CYP21A2*4, CYP21A2*5 and
CC       CYP21A2*6. The sequence shown corresponds to allele CYP21A2*1B.
CC       Deleterious alleles are mostly generated by recombinations between
CC       CYP21A2 and the pseudogene CYP21A1P through gene conversion. This
CC       process consists of recombination events that either delete
CC       CYP21A2 or transfer deleterious mutations from CYP21A1P to
CC       CYP21A2.
CC   -!- DISEASE: Adrenal hyperplasia 3 (AH3) [MIM:201910]: A form of
CC       congenital adrenal hyperplasia, a common recessive disease due to
CC       defective synthesis of cortisol. Congenital adrenal hyperplasia is
CC       characterized by androgen excess leading to ambiguous genitalia in
CC       affected females, rapid somatic growth during childhood in both
CC       sexes with premature closure of the epiphyses and short adult
CC       stature. Four clinical types: 'salt wasting' (SW, the most severe
CC       type), 'simple virilizing' (SV, less severely affected patients),
CC       with normal aldosterone biosynthesis, 'non-classic form' or late-
CC       onset (NC or LOAH) and 'cryptic' (asymptomatic).
CC       {ECO:0000269|PubMed:10051010, ECO:0000269|PubMed:10094562,
CC       ECO:0000269|PubMed:10198222, ECO:0000269|PubMed:10364682,
CC       ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10408778,
CC       ECO:0000269|PubMed:10408786, ECO:0000269|PubMed:10443693,
CC       ECO:0000269|PubMed:10496074, ECO:0000269|PubMed:10720040,
CC       ECO:0000269|PubMed:11232002, ECO:0000269|PubMed:11598371,
CC       ECO:0000269|PubMed:11600539, ECO:0000269|PubMed:11746135,
CC       ECO:0000269|PubMed:12213891, ECO:0000269|PubMed:12222711,
CC       ECO:0000269|PubMed:12788866, ECO:0000269|PubMed:12887291,
CC       ECO:0000269|PubMed:12915679, ECO:0000269|PubMed:1406699,
CC       ECO:0000269|PubMed:1406709, ECO:0000269|PubMed:14676460,
CC       ECO:0000269|PubMed:14715874, ECO:0000269|PubMed:1496017,
CC       ECO:0000269|PubMed:15110320, ECO:0000269|PubMed:15126570,
CC       ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:1644925,
CC       ECO:0000269|PubMed:16984992, ECO:0000269|PubMed:18319307,
CC       ECO:0000269|PubMed:18381579, ECO:0000269|PubMed:18445671,
CC       ECO:0000269|PubMed:1864962, ECO:0000269|PubMed:1937474,
CC       ECO:0000269|PubMed:20080860, ECO:0000269|PubMed:2072928,
CC       ECO:0000269|PubMed:21169732, ECO:0000269|PubMed:22014889,
CC       ECO:0000269|PubMed:2303461, ECO:0000269|PubMed:27721825,
CC       ECO:0000269|PubMed:3038528, ECO:0000269|PubMed:3257825,
CC       ECO:0000269|PubMed:3260007, ECO:0000269|PubMed:3267225,
CC       ECO:0000269|PubMed:3497399, ECO:0000269|PubMed:3871526,
CC       ECO:0000269|PubMed:7749410, ECO:0000269|PubMed:8478006,
CC       ECO:0000269|PubMed:8485582, ECO:0000269|PubMed:8989258,
CC       ECO:0000269|PubMed:9067760, ECO:0000269|PubMed:9187661,
CC       ECO:0000269|PubMed:9497336, ECO:0000269|PubMed:9580109}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP21A2 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp21.htm";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CYP21A2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M12792; AAB59440.1; -; Genomic_DNA.
DR   EMBL; M13936; AAA59695.1; -; Genomic_DNA.
DR   EMBL; M26856; AAA52064.1; -; Genomic_DNA.
DR   EMBL; X58906; CAA41709.1; -; Genomic_DNA.
DR   EMBL; GQ222286; ACT35412.1; -; Genomic_DNA.
DR   EMBL; GQ222296; ACT35422.1; -; Genomic_DNA.
DR   EMBL; GQ222301; ACT35427.1; -; Genomic_DNA.
DR   EMBL; AK054616; BAB70774.1; -; mRNA.
DR   EMBL; AL645922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL844853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL929593; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX679671; CAM26070.1; -; Genomic_DNA.
DR   EMBL; CR753845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03570.1; -; Genomic_DNA.
DR   EMBL; CR936924; CAQ07659.1; -; Genomic_DNA.
DR   EMBL; BC125182; AAI25183.1; -; mRNA.
DR   EMBL; K02771; AAA59706.1; -; Genomic_DNA.
DR   EMBL; M19711; AAA83248.1; -; Genomic_DNA.
DR   EMBL; M17252; AAA59985.1; -; mRNA.
DR   CCDS; CCDS47406.1; -. [P08686-2]
DR   PIR; A25446; O4HUC2.
DR   RefSeq; NP_000491.4; NM_000500.7.
DR   RefSeq; NP_001122062.3; NM_001128590.3.
DR   UniGene; Hs.654479; -.
DR   PDB; 2GEG; Model; -; C=27-494.
DR   PDB; 4Y8W; X-ray; 2.64 A; A/B/C=29-494.
DR   PDBsum; 2GEG; -.
DR   PDBsum; 4Y8W; -.
DR   ProteinModelPortal; P08686; -.
DR   SMR; P08686; -.
DR   STRING; 9606.ENSP00000408860; -.
DR   BindingDB; P08686; -.
DR   ChEMBL; CHEMBL2759; -.
DR   DrugBank; DB01026; Ketoconazole.
DR   SwissLipids; SLP:000001618; -.
DR   iPTMnet; P08686; -.
DR   PhosphoSitePlus; P08686; -.
DR   BioMuta; CYP21A2; -.
DR   DMDM; 117275; -.
DR   PaxDb; P08686; -.
DR   PeptideAtlas; P08686; -.
DR   PRIDE; P08686; -.
DR   Ensembl; ENST00000383321; ENSP00000372811; ENSG00000206338.
DR   Ensembl; ENST00000434026; ENSP00000392321; ENSG00000232414.
DR   Ensembl; ENST00000435122; ENSP00000415043; ENSG00000231852.
DR   Ensembl; ENST00000436607; ENSP00000403721; ENSG00000235134. [P08686-1]
DR   Ensembl; ENST00000448314; ENSP00000398594; ENSG00000198457. [P08686-1]
DR   Ensembl; ENST00000452386; ENSP00000403230; ENSG00000233151.
DR   GeneID; 1589; -.
DR   KEGG; hsa:1589; -.
DR   UCSC; uc003nzf.3; human. [P08686-1]
DR   CTD; 1589; -.
DR   DisGeNET; 1589; -.
DR   GeneCards; CYP21A2; -.
DR   H-InvDB; HIX0057724; -.
DR   H-InvDB; HIX0166983; -.
DR   HGNC; HGNC:2600; CYP21A2.
DR   HPA; HPA048979; -.
DR   HPA; HPA053371; -.
DR   MalaCards; CYP21A2; -.
DR   MIM; 201910; phenotype.
DR   MIM; 613815; gene.
DR   neXtProt; NX_P08686; -.
DR   Orphanet; 315306; Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form.
DR   Orphanet; 315311; Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form.
DR   Orphanet; 95698; Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
DR   PharmGKB; PA27096; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   HOGENOM; HOG000036991; -.
DR   HOVERGEN; HBG106944; -.
DR   InParanoid; P08686; -.
DR   KO; K00513; -.
DR   OrthoDB; EOG091G074I; -.
DR   PhylomeDB; P08686; -.
DR   BioCyc; MetaCyc:HS09769-MONOMER; -.
DR   BRENDA; 1.14.99.10; 2681.
DR   Reactome; R-HSA-193993; Mineralocorticoid biosynthesis.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   GeneWiki; 21-Hydroxylase; -.
DR   GenomeRNAi; 1589; -.
DR   PRO; PR:P08686; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000198457; -.
DR   CleanEx; HS_CYP21A2; -.
DR   ExpressionAtlas; P08686; baseline and differential.
DR   Genevisible; P08686; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004509; F:steroid 21-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008395; F:steroid hydroxylase activity; IMP:UniProtKB.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006705; P:mineralocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006694; P:steroid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IMP:UniProtKB.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Congenital adrenal hyperplasia; Disease mutation;
KW   Endoplasmic reticulum; Heme; Iron; Lipid-binding; Membrane;
KW   Metal-binding; Microsome; Monooxygenase; Oxidoreductase; Polymorphism;
KW   Reference proteome; Steroid-binding; Steroidogenesis.
FT   CHAIN         1    494       Steroid 21-hydroxylase.
FT                                /FTId=PRO_0000051976.
FT   REGION      342    358       Steroid-binding. {ECO:0000250}.
FT   METAL       428    428       Iron (heme axial ligand).
FT                                {ECO:0000269|PubMed:25855791}.
FT   BINDING     233    233       Substrate. {ECO:0000269|PubMed:25855791}.
FT   VAR_SEQ       6      6       L -> LL (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046264.
FT   VAR_SEQ      68    102       VVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSK -> KL
FT                                VSR (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046265.
FT   VARIANT       9      9       L -> LL (in allele CYP21A2*2).
FT                                {ECO:0000269|PubMed:1406709,
FT                                ECO:0000269|PubMed:2303461,
FT                                ECO:0000269|PubMed:3038528,
FT                                ECO:0000269|PubMed:3267225}.
FT                                /FTId=VAR_018363.
FT   VARIANT      12     12       L -> M (in AH3; non-classic form; unknown
FT                                pathological significance; no effect on
FT                                steroid 21-monooxygenase activity).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077582.
FT   VARIANT      15     15       A -> T (in AH3; salt wasting form;
FT                                unknown patholgical significance; no
FT                                significant difference in steroid 21-
FT                                monooxygenase activity;
FT                                dbSNP:rs63749090).
FT                                {ECO:0000269|PubMed:12887291,
FT                                ECO:0000269|PubMed:15126570}.
FT                                /FTId=VAR_026059.
FT   VARIANT      16     16       R -> C (decreased steroid 21-
FT                                monooxygenase activity;
FT                                dbSNP:rs757608533).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077583.
FT   VARIANT      30     30       P -> L (in AH3; non-classic form; 10% of
FT                                non-classic AH3 Texan patients; 50%
FT                                steroid 21-monooxygenase activity;
FT                                dbSNP:rs9378251).
FT                                {ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:10720040,
FT                                ECO:0000269|PubMed:11232002,
FT                                ECO:0000269|PubMed:11598371,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12222711,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12887291,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:15126570,
FT                                ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:1644925,
FT                                ECO:0000269|PubMed:18319307,
FT                                ECO:0000269|PubMed:2072928}.
FT                                /FTId=VAR_001281.
FT   VARIANT      30     30       P -> Q (in AH3; does not affect membrane
FT                                binding; enzyme function abolished).
FT                                {ECO:0000269|PubMed:10198222}.
FT                                /FTId=VAR_026060.
FT   VARIANT      56     56       G -> R (in AH3; loss of activity).
FT                                {ECO:0000269|PubMed:18381579}.
FT                                /FTId=VAR_065668.
FT   VARIANT      62     62       H -> L (in AH3; non-classic form; simple
FT                                virilizing form when associated with a
FT                                second mild mutation such as S-453 or L-
FT                                30; activity is significantly reduced in
FT                                association with S-453; dbSNP:rs9378252).
FT                                {ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:18319307,
FT                                ECO:0000269|PubMed:18381579}.
FT                                /FTId=VAR_018364.
FT   VARIANT      64     64       G -> E (in AH3; no activity).
FT                                {ECO:0000269|PubMed:10408778}.
FT                                /FTId=VAR_007923.
FT   VARIANT      77     77       I -> T (in AH3; simple virilizing form).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065669.
FT   VARIANT      90     90       G -> V (in AH3).
FT                                {ECO:0000269|PubMed:10364682}.
FT                                /FTId=VAR_026061.
FT   VARIANT      98     98       K -> R.
FT                                /FTId=VAR_001282.
FT   VARIANT     102    102       K -> R (in allele CYP21A2*3;
FT                                dbSNP:rs6474).
FT                                {ECO:0000269|PubMed:1406709,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:3038528}.
FT                                /FTId=VAR_001283.
FT   VARIANT     105    105       P -> L (in AH3; dbSNP:rs550051210).
FT                                {ECO:0000269|PubMed:1496017,
FT                                ECO:0000269|PubMed:8989258}.
FT                                /FTId=VAR_001284.
FT   VARIANT     107    107       L -> R (in AH3; loss of activity).
FT                                {ECO:0000269|PubMed:18381579}.
FT                                /FTId=VAR_065670.
FT   VARIANT     113    113       S -> F (in AH3; non-classic form; loss of
FT                                steroid 21-monooxygenase activity).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077584.
FT   VARIANT     121    121       K -> Q (in AH3; non-classic form; reduced
FT                                activity; decreased affinity for 17-
FT                                hydroxyprogesterone and progesterone;
FT                                dbSNP:rs547552654).
FT                                {ECO:0000269|PubMed:18445671}.
FT                                /FTId=VAR_065671.
FT   VARIANT     124    124       R -> H (in AH3; dbSNP:rs72552750).
FT                                {ECO:0000269|PubMed:14676460}.
FT                                /FTId=VAR_026062.
FT   VARIANT     142    142       L -> P (in AH3; loss of activity).
FT                                {ECO:0000269|PubMed:18381579}.
FT                                /FTId=VAR_065672.
FT   VARIANT     167    167       L -> P (in AH3; salt wasting form; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065673.
FT   VARIANT     169    169       C -> R (in AH3; exhibits low hydroxylase
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone).
FT                                {ECO:0000269|PubMed:16984992}.
FT                                /FTId=VAR_075372.
FT   VARIANT     169    169       C -> Y (in AH3).
FT                                {ECO:0000269|PubMed:10094562}.
FT                                /FTId=VAR_001285.
FT   VARIANT     172    172       I -> N (in AH3; simple virilizing form;
FT                                1-4% activity; dbSNP:rs6475).
FT                                {ECO:0000269|PubMed:10051010,
FT                                ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:10720040,
FT                                ECO:0000269|PubMed:11232002,
FT                                ECO:0000269|PubMed:11598371,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12222711,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12887291,
FT                                ECO:0000269|PubMed:12915679,
FT                                ECO:0000269|PubMed:14715874,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:1644925,
FT                                ECO:0000269|PubMed:18319307,
FT                                ECO:0000269|PubMed:18381579,
FT                                ECO:0000269|PubMed:1937474,
FT                                ECO:0000269|PubMed:20080860,
FT                                ECO:0000269|PubMed:2303461,
FT                                ECO:0000269|PubMed:3257825,
FT                                ECO:0000269|PubMed:3871526,
FT                                ECO:0000269|PubMed:7749410,
FT                                ECO:0000269|PubMed:8485582}.
FT                                /FTId=VAR_001286.
FT   VARIANT     178    178       G -> A (in AH3; dbSNP:rs72552751).
FT                                {ECO:0000269|PubMed:10364682}.
FT                                /FTId=VAR_026063.
FT   VARIANT     178    178       G -> R (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone; dbSNP:rs772317717).
FT                                {ECO:0000269|PubMed:16984992}.
FT                                /FTId=VAR_075373.
FT   VARIANT     183    183       D -> E (in allele CYP21A2*4;
FT                                dbSNP:rs1040310).
FT                                /FTId=VAR_001287.
FT   VARIANT     191    191       Y -> H (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone).
FT                                {ECO:0000269|PubMed:22014889}.
FT                                /FTId=VAR_075374.
FT   VARIANT     196    196       Missing (in AH3; moderate).
FT                                {ECO:0000269|PubMed:9497336}.
FT                                /FTId=VAR_008688.
FT   VARIANT     198    198       L -> F (in AH3; dbSNP:rs143240527).
FT                                {ECO:0000269|PubMed:21169732}.
FT                                /FTId=VAR_075375.
FT   VARIANT     202    202       S -> G (decreased steroid 21-
FT                                monooxygenase activity;
FT                                dbSNP:rs372964292).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077585.
FT   VARIANT     211    211       V -> L (in AH3; non-classic form;
FT                                pathogenicity uncertain).
FT                                {ECO:0000269|PubMed:3260007}.
FT                                /FTId=VAR_026064.
FT   VARIANT     230    230       I -> T (in AH3).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065674.
FT   VARIANT     233    233       R -> K (in AH3).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065675.
FT   VARIANT     236    236       I -> N (in AH3; salt wasting form;
FT                                dbSNP:rs111647200).
FT                                {ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:1644925,
FT                                ECO:0000269|PubMed:7749410}.
FT                                /FTId=VAR_001288.
FT   VARIANT     237    237       V -> E (in AH3; salt wasting form;
FT                                dbSNP:rs12530380).
FT                                {ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:1644925}.
FT                                /FTId=VAR_001289.
FT   VARIANT     239    239       M -> K (in AH3; salt wasting form;
FT                                dbSNP:rs6476).
FT                                {ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:1644925}.
FT                                /FTId=VAR_001290.
FT   VARIANT     261    261       L -> P (in AH3; dbSNP:rs750337015).
FT                                {ECO:0000269|PubMed:11598371}.
FT                                /FTId=VAR_026065.
FT   VARIANT     267    267       P -> L (decreased steroid 21-
FT                                monooxygenase activity;
FT                                dbSNP:rs142028935).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077586.
FT   VARIANT     268    268       S -> T (in allele CYP21A2*5;
FT                                dbSNP:rs6472).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:2072928,
FT                                ECO:0000269|PubMed:3038528}.
FT                                /FTId=VAR_001291.
FT   VARIANT     281    281       V -> G (in AH3; salt wasting form).
FT                                {ECO:0000269|PubMed:10720040}.
FT                                /FTId=VAR_026066.
FT   VARIANT     281    281       V -> L (in AH3; non-classic form; 50%
FT                                activity; most common variant; normal KM
FT                                but 20% reduced Vmax; dbSNP:rs6471).
FT                                {ECO:0000269|PubMed:10094562,
FT                                ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:10443693,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:10720040,
FT                                ECO:0000269|PubMed:11232002,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12222711,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12887291,
FT                                ECO:0000269|PubMed:12915679,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:15126570,
FT                                ECO:0000269|PubMed:1644925,
FT                                ECO:0000269|PubMed:1864962,
FT                                ECO:0000269|PubMed:20080860,
FT                                ECO:0000269|PubMed:3260007,
FT                                ECO:0000269|PubMed:3267225,
FT                                ECO:0000269|PubMed:3497399,
FT                                ECO:0000269|PubMed:7749410}.
FT                                /FTId=VAR_001292.
FT   VARIANT     282    282       H -> N (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone).
FT                                {ECO:0000269|PubMed:22014889}.
FT                                /FTId=VAR_075376.
FT   VARIANT     283    283       M -> L (in AH3).
FT                                {ECO:0000269|PubMed:12222711}.
FT                                /FTId=VAR_026067.
FT   VARIANT     291    291       G -> C (in AH3).
FT                                {ECO:0000269|PubMed:10364682}.
FT                                /FTId=VAR_026068.
FT   VARIANT     291    291       G -> R (in AH3; dbSNP:rs201552310).
FT                                {ECO:0000269|PubMed:12915679}.
FT                                /FTId=VAR_018365.
FT   VARIANT     291    291       G -> S (in AH3; salt wasting form; less
FT                                then 1% activity; dbSNP:rs201552310).
FT                                {ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:1496017,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:20080860,
FT                                ECO:0000269|PubMed:9497336}.
FT                                /FTId=VAR_001293.
FT   VARIANT     292    292       G -> D (in AH3; salt wasting form; less
FT                                then 1% activity).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065676.
FT   VARIANT     300    300       L -> F (in AH3; salt wasting form;
FT                                dbSNP:rs765001985).
FT                                {ECO:0000269|PubMed:10720040}.
FT                                /FTId=VAR_026069.
FT   VARIANT     301    301       S -> Y (in AH3).
FT                                {ECO:0000269|PubMed:12915679}.
FT                                /FTId=VAR_018366.
FT   VARIANT     302    302       W -> R (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone).
FT                                {ECO:0000269|PubMed:16984992}.
FT                                /FTId=VAR_075377.
FT   VARIANT     304    304       V -> M (in hyperandrogenism; due to 21-
FT                                hydroxylase deficiency; non-classic type;
FT                                residual activity of 46% for conversion
FT                                of 17-hydroxyprogesterone and 26% for
FT                                conversion of progesterone compared with
FT                                the normal enzyme; dbSNP:rs151344505).
FT                                {ECO:0000269|PubMed:12050257}.
FT                                /FTId=VAR_026070.
FT   VARIANT     317    317       L -> M (in AH3).
FT                                {ECO:0000269|PubMed:11232002}.
FT                                /FTId=VAR_026071.
FT   VARIANT     320    320       E -> K (in AH3; simple virilizing form;
FT                                4% activity).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065677.
FT   VARIANT     339    339       R -> H (in AH3; non-classic form; 50%
FT                                activity; dbSNP:rs72552754).
FT                                {ECO:0000269|PubMed:1406709}.
FT                                /FTId=VAR_001294.
FT   VARIANT     341    341       R -> P (in AH3; simple virilizing form).
FT                                {ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12915679,
FT                                ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_018367.
FT   VARIANT     341    341       R -> W (in AH3; non-classic form; mild;
FT                                dbSNP:rs777860817).
FT                                /FTId=VAR_001295.
FT   VARIANT     354    354       R -> C (in AH3; salt wasting form;
FT                                dbSNP:rs772900496).
FT                                {ECO:0000269|PubMed:10720040}.
FT                                /FTId=VAR_026072.
FT   VARIANT     354    354       R -> H (in AH3; salt wasting form;
FT                                dbSNP:rs760216630).
FT                                {ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_026073.
FT   VARIANT     356    356       R -> P (in AH3; salt wasting form; 0.15%
FT                                activity). {ECO:0000269|PubMed:9187661}.
FT                                /FTId=VAR_001296.
FT   VARIANT     356    356       R -> Q (in AH3; simple virilizing form;
FT                                mild; 0.65% activity; dbSNP:rs574370139).
FT                                {ECO:0000269|PubMed:10094562,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:9187661}.
FT                                /FTId=VAR_001297.
FT   VARIANT     356    356       R -> W (in AH3; salt wasting form;
FT                                dbSNP:rs7769409).
FT                                {ECO:0000269|PubMed:10051010,
FT                                ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:10408778,
FT                                ECO:0000269|PubMed:10408786,
FT                                ECO:0000269|PubMed:10443693,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:10720040,
FT                                ECO:0000269|PubMed:11232002,
FT                                ECO:0000269|PubMed:11598371,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12222711,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12915679,
FT                                ECO:0000269|PubMed:14715874,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:1644925,
FT                                ECO:0000269|PubMed:18319307,
FT                                ECO:0000269|PubMed:18381579,
FT                                ECO:0000269|PubMed:20080860,
FT                                ECO:0000269|PubMed:2303461}.
FT                                /FTId=VAR_001298.
FT   VARIANT     362    362       A -> V (in AH3; no activity).
FT                                {ECO:0000269|PubMed:10408778}.
FT                                /FTId=VAR_007924.
FT   VARIANT     363    363       L -> W (in AH3).
FT                                {ECO:0000269|PubMed:11746135}.
FT                                /FTId=VAR_026074.
FT   VARIANT     365    365       H -> Y (in AH3).
FT                                {ECO:0000269|PubMed:15110320}.
FT                                /FTId=VAR_026075.
FT   VARIANT     369    369       R -> W (in AH3; dbSNP:rs781074931).
FT                                {ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_065678.
FT   VARIANT     375    375       G -> S (in hyperandrogenism; due to 21-
FT                                hydroxylase deficiency; almost completely
FT                                abolished enzyme activity;
FT                                dbSNP:rs151344506).
FT                                {ECO:0000269|PubMed:12050257}.
FT                                /FTId=VAR_026076.
FT   VARIANT     380    380       E -> D (in AH3; salt wasting form;
FT                                dbSNP:rs72552756).
FT                                {ECO:0000269|PubMed:9067760}.
FT                                /FTId=VAR_001299.
FT   VARIANT     389    391       Missing (in AH3; salt wasting form; loss
FT                                of steroid 21-monooxygenase activity).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077587.
FT   VARIANT     408    408       R -> C (in AH3; very low residual
FT                                activity; dbSNP:rs72552757).
FT                                {ECO:0000269|PubMed:12213891,
FT                                ECO:0000269|PubMed:18381579,
FT                                ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_026077.
FT   VARIANT     424    424       G -> S (in AH3; very low activity;
FT                                dbSNP:rs72552758).
FT                                {ECO:0000269|PubMed:10443693,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12213891,
FT                                ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_026078.
FT   VARIANT     426    426       R -> C (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone
FT                                and progesterone).
FT                                {ECO:0000269|PubMed:16984992}.
FT                                /FTId=VAR_075378.
FT   VARIANT     426    426       R -> H (in AH3; exhibits low enzymatic
FT                                activity toward 17-hydroxyprogesterone;
FT                                dbSNP:rs151344504).
FT                                {ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:20080860}.
FT                                /FTId=VAR_026079.
FT   VARIANT     435    435       R -> C (in AH3; dbSNP:rs767333157).
FT                                {ECO:0000269|PubMed:11232002}.
FT                                /FTId=VAR_026080.
FT   VARIANT     450    450       T -> M (decreased steroid 21-
FT                                monooxygenase activity).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077588.
FT   VARIANT     450    450       T -> P (in AH3; salt wasting form; loss
FT                                of steroid 21-monooxygenase activity).
FT                                {ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_077589.
FT   VARIANT     453    453       P -> S (in AH3; non-classic form; simple
FT                                virilizing form when associated with L-
FT                                62; 50% of activity; almost completely
FT                                abolished enzyme activity when associated
FT                                with S-375; dbSNP:rs6445).
FT                                {ECO:0000269|PubMed:10364682,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10720040,
FT                                ECO:0000269|PubMed:11232002,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12050257,
FT                                ECO:0000269|PubMed:12222711,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:12887291,
FT                                ECO:0000269|PubMed:1406699,
FT                                ECO:0000269|PubMed:1406709,
FT                                ECO:0000269|PubMed:1496017,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:18319307,
FT                                ECO:0000269|PubMed:18381579,
FT                                ECO:0000269|PubMed:18445671,
FT                                ECO:0000269|PubMed:20080860,
FT                                ECO:0000269|PubMed:8989258}.
FT                                /FTId=VAR_001300.
FT   VARIANT     479    479       R -> L (in AH3; dbSNP:rs184649564).
FT                                {ECO:0000269|PubMed:15110320}.
FT                                /FTId=VAR_026081.
FT   VARIANT     482    482       P -> S (in AH3; reduced enzyme activity
FT                                to 70% of normal; dbSNP:rs776989258).
FT                                {ECO:0000269|PubMed:15126570,
FT                                ECO:0000269|PubMed:27721825}.
FT                                /FTId=VAR_026082.
FT   VARIANT     483    483       R -> P (in AH3; moderate; 1-2% of
FT                                activity; dbSNP:rs200005406).
FT                                {ECO:0000269|PubMed:11598371,
FT                                ECO:0000269|PubMed:11600539,
FT                                ECO:0000269|PubMed:12788866,
FT                                ECO:0000269|PubMed:15110320,
FT                                ECO:0000269|PubMed:7749410,
FT                                ECO:0000269|PubMed:8478006,
FT                                ECO:0000269|PubMed:9497336}.
FT                                /FTId=VAR_001301.
FT   VARIANT     483    483       R -> Q (in AH3; dbSNP:rs200005406).
FT                                {ECO:0000269|PubMed:12915679}.
FT                                /FTId=VAR_018368.
FT   VARIANT     483    483       R -> W (in AH3; salt wasting form;
FT                                dbSNP:rs759736443).
FT                                {ECO:0000269|PubMed:14715874}.
FT                                /FTId=VAR_026083.
FT   VARIANT     493    493       N -> S (in allele CYP21A2*6;
FT                                dbSNP:rs6473).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10496074,
FT                                ECO:0000269|PubMed:1406709,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:3038528,
FT                                ECO:0000269|PubMed:7749410}.
FT                                /FTId=VAR_001302.
FT   MUTAGEN     268    268       S->C,M,T: No loss of function.
FT                                {ECO:0000269|PubMed:1864962}.
FT   MUTAGEN     281    281       V->I: Normal KM but 50% reduced Vmax.
FT   MUTAGEN     281    281       V->T: Normal KM but 10% reduced Vmax.
FT   MUTAGEN     428    428       C->M,S,T: Loss of activity and loss of
FT                                P450 absorption.
FT                                {ECO:0000269|PubMed:1864962}.
FT   CONFLICT    155    155       G -> D (in Ref. 7; BAB70774).
FT                                {ECO:0000305}.
FT   CONFLICT    242    242       R -> G (in Ref. 7; BAB70774).
FT                                {ECO:0000305}.
FT   CONFLICT    277    277       L -> Q (in Ref. 7; BAB70774).
FT                                {ECO:0000305}.
FT   CONFLICT    304    304       V -> A (in Ref. 7; BAB70774).
FT                                {ECO:0000305}.
FT   CONFLICT    311    311       P -> L (in Ref. 14; AAA59985).
FT                                {ECO:0000305}.
FT   CONFLICT    346    346       N -> I (in Ref. 14; AAA59985).
FT                                {ECO:0000305}.
FT   CONFLICT    426    426       R -> P (in Ref. 1; AAB59440).
FT                                {ECO:0000305}.
FT   CONFLICT    437    437       E -> D (in Ref. 1; AAB59440).
FT                                {ECO:0000305}.
FT   HELIX        38     40       {ECO:0000244|PDB:4Y8W}.
FT   HELIX        44     50       {ECO:0000244|PDB:4Y8W}.
FT   HELIX        52     55       {ECO:0000244|PDB:4Y8W}.
FT   STRAND       57     63       {ECO:0000244|PDB:4Y8W}.
FT   STRAND       66     71       {ECO:0000244|PDB:4Y8W}.
FT   HELIX        74     81       {ECO:0000244|PDB:4Y8W}.
FT   TURN         82     84       {ECO:0000244|PDB:4Y8W}.
FT   HELIX        85     88       {ECO:0000244|PDB:4Y8W}.
FT   HELIX        95     99       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       114    128       {ECO:0000244|PDB:4Y8W}.
FT   TURN        129    134       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       135    150       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       160    177       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       179    182       {ECO:0000244|PDB:4Y8W}.
FT   TURN        183    185       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       187    201       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       204    211       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       213    216       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       223    245       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       256    261       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       278    309       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       311    324       {ECO:0000244|PDB:4Y8W}.
FT   TURN        336    338       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       343    355       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      369    373       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      376    378       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      383    386       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       388    392       {ECO:0000244|PDB:4Y8W}.
FT   TURN        395    397       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      398    400       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       406    409       {ECO:0000244|PDB:4Y8W}.
FT   HELIX       431    446       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      449    457       {ECO:0000244|PDB:4Y8W}.
FT   STRAND      478    482       {ECO:0000244|PDB:4Y8W}.
SQ   SEQUENCE   494 AA;  55887 MW;  7E1FF83B59FBA136 CRC64;
     MLLLGLLLLP LLAGARLLWN WWKLRSLHLP PLAPGFLHLL QPDLPIYLLG LTQKFGPIYR
     LHLGLQDVVV LNSKRTIEEA MVKKWADFAG RPEPLTYKLV SKNYPDLSLG DYSLLWKAHK
     KLTRSALLLG IRDSMEPVVE QLTQEFCERM RAQPGTPVAI EEEFSLLTCS IICYLTFGDK
     IKDDNLMPAY YKCIQEVLKT WSHWSIQIVD VIPFLRFFPN PGLRRLKQAI EKRDHIVEMQ
     LRQHKESLVA GQWRDMMDYM LQGVAQPSME EGSGQLLEGH VHMAAVDLLI GGTETTANTL
     SWAVVFLLHH PEIQQRLQEE LDHELGPGAS SSRVPYKDRA RLPLLNATIA EVLRLRPVVP
     LALPHRTTRP SSISGYDIPE GTVIIPNLQG AHLDETVWER PHEFWPDRFL EPGKNSRALA
     FGCGARVCLG EPLARLELFV VLTRLLQAFT LLPSGDALPS LQPLPHCSVI LKMQPFQVRL
     QPRGMGAHSP GQNQ
//
